StemCells Inc. (STEM)
-NasdaqCM | Prev Close: | 1.68 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 3.58 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 4-Nov-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.40 - 2.50 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 364,395 |
|---|
| Market Cap: | 69.39M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: StemCells announces proposed public offering of common stock; size not disclosedBriefing.com(Tue, Oct 1)
- StemCells, Inc. Announces Proposed Public Offering of Common Stock and WarrantsGlobeNewswire(Tue, Oct 1)
- StemCells, Inc. Announces New Preclinical Data Showing HuCNS-SC(R) Cells Preserve Visual Function by Keeping Photoreceptors Normal and HealthyGlobeNewswire(Wed, Sep 18)
- STEMCELLS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Thu, Sep 12)
- StemCells announce first transplant in phase 1,2 trial in AMDtheflyonthewall.com(Thu, Sep 12)
- Stemcells, Inc. Announces First High-Dose Patient Transplanted in Phase I/II Clinical Trial in Dry Age-Related Macular DegenerationGlobeNewswire(Thu, Sep 12)
- Why Neuralstem Represents An Enormous Opportunity For Investorsat Seeking Alpha(Mon, Sep 9)
- StemCells, Inc. Publishes Comprehensive Review of Results From HuCNS-SC Clinical TrialsGlobeNewswire(Mon, Sep 9)
- Biotech: A Scattershot Of Stem Cell Plays Following Yesterday's Bloodbathat Seeking Alpha(Tue, Aug 27)
- STEMCELLS INC FinancialsEDGAR Online Financials(Tue, Aug 20)
- StemCells Management Discusses Q2 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Aug 7)
- StemCells, Inc. Earnings Call scheduled for 4:30 pm ET todayCCBN(Wed, Aug 7)
- StemCells Inc. Management Discusses Q2 2013 Results (Webcast)at Seeking Alpha(Wed, Aug 7)
- StemCells, Inc. Reports Second Quarter 2013 Financial Results and Provides Business UpdateGlobeNewswire(Wed, Aug 7)
- STEMCELLS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, Aug 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 66.66 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.59 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.14 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States.
View More